普拉苏格勒在皮肤冠状动脉干预后对脑血管事件的预防作用
Hisaki Makimoto1,2,3, Yusuke Sasabuchi4, Tomoyuki Kabutoya1
1Division of Cardiovascular Medicine, Department of Medicine (H.M., T. Kabutoya, T. Kohro, Y.O., Y.I., K.K.), Jichi Medical University School of Medicine, Shimotsuke, Japan.
Stroke
|May 23, 2025
概括
通过皮肤冠状动脉干预 (PCI) 后使用prasugrel显著降低了脑血管事件,而不是克洛皮多格雷尔. 这项研究强调了普拉苏格勒的作用.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 通过皮肤冠状动脉干预 (PCI) 放置支架后,双重抗血小板治疗是标准的.
- 普拉苏格勒是一种P2Y12抑制剂,显示出比克洛皮多格雷尔更大的心血管事件抑制,但其PCI后的脑血管益处仍在争论中.
- 这项研究调查了普拉苏格勒与克洛皮多格雷尔在日本PCI后患者的真实脑血管功效和安全性.
研究的目的:
- 在接受PCI的患者中比较普拉苏格勒和克洛皮多格勒的脑血管疗效和安全性.
- 为了评估两种药物组之间的整体中风,缺血性中风和出血性中风的发生率.
- 评估与普拉苏格勒相关的1年医疗费用与PCI后的克洛皮多格勒治疗相比.
主要方法:
- 利用CLIDAS数据库确定7412名接受PCI后 (2013年4月至2019年3月) 双重抗血小板治疗的患者.
- 主要终点定义为任何中风;次要终点包括缺血性和出血性脑血管事件.
- 使用的倾向性得分对治疗权重的逆概率和Prasugrel和Clopidogrel组之间的比较分析的Fine和Grey模型.
主要成果:
- 在PCI后1年内,普拉苏格勒组的脑血管事件发生率显著降低 (分发危险比率,0.46;P=0.027).
- 亚组分析显示,普拉苏格雷尔和克洛皮多格雷尔之间的缺血性 (P=0.11) 或出血性脑血管事件 (P=0.070) 没有显著差异.
- 治疗组之间没有观察到1年医疗保健费用的显著差异.
结论:
- 与克洛皮多格雷尔相比,PCI后使用普拉苏格勒与脑血管事件的减少有关.
- 需要进一步的研究来证实普拉苏格勒在减轻PCI后脑血管风险方面的潜力.
- 普拉苏格勒似乎在PCI后提供了脑血管方面的好处,而不会显著影响医疗保健成本.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
656
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
656
Coronary Artery Disease IV: Preventive Measures
41
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
41
Peripheral Artery Disease III: Interprofessional Care
36
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
36
Coronary Artery Disease V: Interprofessional Care
40
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
40
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
261
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
261
Acute Coronary Syndrome IV: Interprofessional Care
34
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
34


